Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study
Systemic lupus erythematosus (SLE) is an autoimmune condition where the immune system attacks healthy tissues. People with lupus often have ongoing swelling, called inflammation, in their blood vessels. This significantly increases their risk of early heart attacks, strokes, and other cardiovascular problems. This clinical study is testing a drug called anifrolumab, which is already used to treat active lupus by blocking specific immune signals. Researchers want to find out whether anifrolumab can also calm down inflammation inside the arteries, the blood vessels that supply the heart. Participants will take anifrolumab alongside their usual lupus medications for 16 weeks. Doctors will measure blood vessel inflammation using advanced scans (PET/MRI and CT scans) and routine blood tests at the beginning and end of the study. The findings may help doctors find better ways to protect people with lupus from heart disease.
At a glance
What is this study about?
Systemic lupus erythematosus, commonly known as lupus or SLE, causes the body's immune system to attack its own organs and tissues. While lupus is well known for causing joint pain, rashes, and fatigue, it also causes long-term inflammation inside the blood vessels. This inflammation can cause arteries to narrow and stiffen, putting people with lupus—especially young women—at a much higher risk of heart attacks and strokes compared to the general population.
Doctors want to know whether medicines that treat lupus flares can also protect the heart and arteries. This study focuses on a drug called anifrolumab. Anifrolumab works by blocking a protein called type I interferon, which plays a major part in driving the harmful immune response in lupus. Researchers want to see if calming this pathway also cools down swelling in the arteries.
To see what is happening inside the blood vessels, researchers will use advanced imaging called a PET/MRI scan, combined with a safe tracing dye, and a CT scan of the heart's arteries. These detailed pictures allow doctors to spot and measure inflammation before treatment starts and compare it with pictures taken after 16 weeks of receiving anifrolumab.
By taking part, participants help scientists understand whether targeting the immune system can lower the risk of heart disease in lupus. In the long run, this knowledge could also help researchers find new ways to prevent heart attacks and strokes in people without lupus who have inflamed blood vessels.
Key takeaways
- The study tests whether the lupus drug anifrolumab reduces swelling inside blood vessels.
- People with lupus have a significantly higher risk of early heart attacks and strokes.
- Treatment lasts for 16 weeks and is taken alongside your regular lupus medicines.
- Specialised PET/MRI and CT scans will track changes in your arteries before and after treatment.
- Participation is voluntary, and you can stop taking part at any point.
Who may be eligible?
This study is open to adults aged between 18 and 70 who have been diagnosed with active systemic lupus erythematosus (SLE). To be suitable, you need to have active symptoms confirmed by standard lupus activity scores, test positive for specific lupus antibodies, and be on a steady dose of your regular lupus treatments for at least four weeks. Your daily dose of steroid medication (such as prednisolone) must be 7.5 mg or less, and you must be able to lie flat comfortably for imaging scans.
You cannot take part if you are pregnant, planning a pregnancy, breastfeeding, or not using reliable contraception, as the safety of this treatment during pregnancy is not established. People who are already taking anifrolumab, or who have had severe allergic reactions to similar antibody therapies, are also not eligible.
Because anifrolumab dampens down part of the immune system, people with serious or repeated infections cannot take part. This includes active hepatitis B or C, severe or recurrent shingles, or any infection requiring hospital treatment or intravenous antibiotics in recent years. You will also need to be up to date with your routine vaccines, such as the flu and shingles jabs, before joining.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am between 18 and 70 years of age.
- I have a confirmed diagnosis of active systemic lupus erythematosus (SLE).
- My current lupus treatment has been stable for at least 4 weeks, with prednisolone at 7.5 mg daily or less.
- I am able to lie flat comfortably for medical scans.
- I am not pregnant, breastfeeding, or planning a pregnancy during the study.
- I do not have a history of frequent, serious, or recurrent infections such as shingles.
What does participation involve?
Taking part in the study lasts approximately 16 weeks (around 4 months). You will receive anifrolumab in addition to your usual lupus treatments. At the start of the study, you will attend hospital for baseline health checks, blood tests, a CT heart scan, and a specialised PET/MRI scan to look at your blood vessels. You will then have regular study visits to monitor your symptoms and check for any side effects. At the end of the 16-week period, you will have repeat blood tests and scans to see if the inflammation in your blood vessels has decreased.
Potential risks and benefits
Locations (1)
- Addenbrookes HospitalVerified postcodeCambridge, United Kingdom· Recruiting
Common questions
Will I have to stop taking my normal lupus medicines?
No. Participants continue taking their standard, stable lupus treatments alongside the study medicine, provided your daily steroid dose is 7.5 mg of prednisolone or lower.
What happens during a PET/MRI scan?
You will be given a small injection containing a tracking dye that highlights inflamed areas. You will then lie flat inside a scanner while it takes detailed pictures of your heart and blood vessels.
Does the study involve radiation?
Yes. The CT scan and the PET tracer involve small, carefully controlled amounts of medical radiation, similar to tests routinely used in NHS hospitals.
Is anifrolumab a brand-new, untried medicine?
No. Anifrolumab is an approved medicine already used to treat active lupus. This trial is looking specifically at its effects on blood vessel inflammation and heart health.
Can I leave the study early if I want to?
Yes. You are free to withdraw from the trial at any point, for any reason, and your regular doctor will continue providing your normal medical care.
How to find out more
Thomas AJ Bond, MBChB, BMedSci
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.